CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema...
Phase 2
Pflugerville, Texas, United States and 35 other locations
The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pa...
Phase 1
Austin, Texas, United States
This is a Phase 2 open label study of ATI-2138 in participants with moderate to severe atopic dermatitis.
Phase 2
Austin, Texas, United States and 4 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...
Phase 3
Austin, Texas, United States of America and 179 other locations
This is a Phase 2, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S....
Phase 2
Austin, Texas, United States and 9 other locations
/TCI, compared with placebo in combination with TCS/TCI at Week 24, assessed using Eczema Area and Severity Index (EASI)....
Phase 3
Austin, Texas, United States and 234 other locations
This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK10...
Phase 2
Austin, Texas, United States and 95 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
Pflugerville, Texas, United States of America and 558 other locations
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Phase 3
Pflugerville, Texas, United States of America and 320 other locations
assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult pa...
Phase 3
Austin, Texas, United States of America and 61 other locations
Clinical trials
Research sites
Resources
Legal